報價延遲最少15分鐘:2024/12/23 22:24 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.598 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.12/-0.78
|
|
企業價值
21.93M
|
| 資產負債 |
|
每股賬面淨值
0.65
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
15.76M
|
|
每股收益
0.95
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:24 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease. |